Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer

Daniele A Pizzuto, Salvatore Annunziata, Francesco P Ieria, Carmelo Caldarella, Maria A Isgrò, Valerio Lanni, Gaia Bencivenga, Vittoria Rufini, Alessandro Giordano

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.

METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, "trigger" prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or followup (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumour other than PC, and lung metastases from PC.

RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (p=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (p=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/ml/month, IQR 0.65-6.65 ng/ml/month) than in patients without lung PCrelapse (median PSAvel 0.3 ng/ml/month, IQR 0.2-0.5 ng/ml/month). Patients with lung metastases from PC had significantly (p=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).

CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.

Original languageEnglish
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
DOIs
Publication statusE-pub ahead of print - Jan 17 2018

Fingerprint

Fluorine
Choline
Prostatic Neoplasms
Neoplasm Grading
Lung
Neoplasm Metastasis
Lung Neoplasms
Histology
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Androgens
Biomarkers
Inflammation
Recurrence

Cite this

Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. / Pizzuto, Daniele A; Annunziata, Salvatore; Ieria, Francesco P; Caldarella, Carmelo; Isgrò, Maria A; Lanni, Valerio; Bencivenga, Gaia; Rufini, Vittoria; Giordano, Alessandro.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, 17.01.2018.

Research output: Contribution to journalArticle

Pizzuto, Daniele A ; Annunziata, Salvatore ; Ieria, Francesco P ; Caldarella, Carmelo ; Isgrò, Maria A ; Lanni, Valerio ; Bencivenga, Gaia ; Rufini, Vittoria ; Giordano, Alessandro. / Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2018.
@article{0ab70261ff874908b846050005fa44fe,
title = "Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer",
abstract = "BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, {"}trigger{"} prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or followup (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumour other than PC, and lung metastases from PC.RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (p=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (p=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/ml/month, IQR 0.65-6.65 ng/ml/month) than in patients without lung PCrelapse (median PSAvel 0.3 ng/ml/month, IQR 0.2-0.5 ng/ml/month). Patients with lung metastases from PC had significantly (p=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.",
author = "Pizzuto, {Daniele A} and Salvatore Annunziata and Ieria, {Francesco P} and Carmelo Caldarella and Isgr{\`o}, {Maria A} and Valerio Lanni and Gaia Bencivenga and Vittoria Rufini and Alessandro Giordano",
year = "2018",
month = "1",
day = "17",
doi = "10.23736/S1824-4785.18.02985-0",
language = "English",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",

}

TY - JOUR

T1 - Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer

AU - Pizzuto, Daniele A

AU - Annunziata, Salvatore

AU - Ieria, Francesco P

AU - Caldarella, Carmelo

AU - Isgrò, Maria A

AU - Lanni, Valerio

AU - Bencivenga, Gaia

AU - Rufini, Vittoria

AU - Giordano, Alessandro

PY - 2018/1/17

Y1 - 2018/1/17

N2 - BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, "trigger" prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or followup (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumour other than PC, and lung metastases from PC.RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (p=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (p=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/ml/month, IQR 0.65-6.65 ng/ml/month) than in patients without lung PCrelapse (median PSAvel 0.3 ng/ml/month, IQR 0.2-0.5 ng/ml/month). Patients with lung metastases from PC had significantly (p=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.

AB - BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, "trigger" prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or followup (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumour other than PC, and lung metastases from PC.RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (p=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (p=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/ml/month, IQR 0.65-6.65 ng/ml/month) than in patients without lung PCrelapse (median PSAvel 0.3 ng/ml/month, IQR 0.2-0.5 ng/ml/month). Patients with lung metastases from PC had significantly (p=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.

U2 - 10.23736/S1824-4785.18.02985-0

DO - 10.23736/S1824-4785.18.02985-0

M3 - Article

C2 - 29345442

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

ER -